|Bid||0.00 x 1400|
|Ask||0.00 x 900|
|Day's Range||7.04 - 7.35|
|52 Week Range||1.00 - 10.95|
|Beta (5Y Monthly)||2.69|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 22, 2020 - Mar 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 12, 2012|
|1y Target Est||9.00|
Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that The Journal of Prevention of Alzheimer’s Disease (JPAD), a peer-reviewed journal for the research community, published results from the Company’s Phase 2a study demonstrating that its lead drug candidate, PTI-125, reduced biomarkers of disease in Alzheimer’s patients. This publication provides clinical insights into how our lead drug candidate, PTI-125, could make an important difference for patients living with Alzheimer’s disease.
Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced it has initiated dosing for the last patient in a Phase 2b study of PTI-125. This completes patient enrollment in a randomized, double-blind, placebo-controlled, Phase 2b study of PTI-125, Cassava Sciences’ investigational drug to treat Alzheimer’s disease. “This study again brought together leaders from the research community who share our commitment to improving outcomes for patients with Alzheimer’s disease,” said Remi Barbier, President & CEO.
The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences
Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.
Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma
Shares of Cassava Sciences Inc. , which is developing treatments for Alzheimer's disease, jumped 33% on heavy volume in premarket trading on Thursday. The company's president and CEO, Remi Barbier, had acquired 100,000 shares of Cassava's stock on Dec. 31. Barbier had also bought an additional 15,198 shares over the course of December. Cassava's stock rallied 24% in December on positive data from a mid-stage trial for PTI-125, one of its experimental Alzheimer's disease drugs. Cassava's stock is up 463% over the last year, while the S&P 500 has gained 28%.
Shares of Cassava Sciences Inc. jumped 24% on positive data from a mid-stage trial for its experimental Alzheimer's disease drug, PTI-125. The data, which found that the therapy reduced cerebrospinal fluid and plasma biomarkers for Alzheimer's, was released Dec. 5 at the Clinical Trials on Alzheimer's Disease meeting in San Diego. Biogen also released somewhat controversial data about its late-stage Alzheimer's candidate at the conference on Thursday. Cassava stock is up 163% year-to-date. The S&P 500 is up 25%.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented ...
Cassava Sciences, Inc. (SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, today announced additional clinical data from a Phase 2a study of PTI-125, its investigational drug candidate for Alzheimer’s disease. Company scientists presented the new data during a late-breaking oral presentation today at the 12th International Conference on Clinical Trials on Alzheimer’s Disease (CTAD), in San Diego, Ca.
Biotech stocks advanced in the holiday-shortened week, with upside driven mainly by the broader market strength. Reflecting the extreme volatility in the space, a few stocks gyrated wildly in reaction ...
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Cassava Sciences, Inc. (SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, today announced that clinical results of its Phase 2a study of PTI-125 have been selected as a late-breaking oral presentation by the 12th International Conference on Clinical Trials on Alzheimer’s Disease (CTAD). CTAD is a prestigious annual conference focused on Alzheimer’s research and development and takes place this year in San Diego, CA, on December 4-7th, 2019. PTI-125 is Cassava Sciences’ lead drug candidate for Alzheimer’s disease.
PTI-125 is a small molecule that targets the massive neuroinflammation and neurodegeneration observed in the Alzheimer’s brain. In conjunction with the initiation of this Phase 2b study, Cassava Sciences also reported dosing of the first two patients for this study, both of which were uneventful. This Phase 2b study is supported by a research grant award from the National Institutes of Health (NIH).
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. ACADIA Pharmaceuticals (NASDAQ: ACAD ) shares ...